BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24121234)

  • 1. Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.
    Zhang L; Fan C; Guo Z; Li Y; Zhao S; Yang S; Yang Y; Zhu J; Lin D
    Eur J Med Chem; 2013 Nov; 69():833-41. PubMed ID: 24121234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
    Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
    J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
    ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
    Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
    Cha MY; Lee KO; Kim JW; Lee CG; Song JY; Kim YH; Lee GS; Park SB; Kim MS
    J Med Chem; 2009 Nov; 52(21):6880-8. PubMed ID: 19888761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
    Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
    Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
    J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
    Cha MY; Lee KO; Kang SJ; Jung YH; Song JY; Choi KJ; Byun JY; Lee HJ; Lee GS; Park SB; Kim MS
    J Med Chem; 2012 Mar; 55(6):2846-57. PubMed ID: 22372864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
    Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
    Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
    Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
    Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ
    Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
    Li RD; Zhang X; Li QY; Ge ZM; Li RT
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3637-40. PubMed ID: 21570843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
    Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
    Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Acton DG; Ballard P; Bradbury RH; Cross D; Ducray R; Germain H; Hudson K; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Ross HS; Smith R; Trigwell CB; Vautier M; Wright L
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1799-803. PubMed ID: 18313293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
    Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
    Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Ballard P; Barlaam BC; Bradbury RH; Dishington A; Hennequin LF; Hickinson DM; Hollingsworth IM; Kettle JG; Klinowska T; Ogilvie DJ; Pearson SE; Scott JS; Suleman A; Whittaker R; Williams EJ; Wood R; Wright L
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6326-9. PubMed ID: 17869514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.